4-methyl-N-[4-methyl-3-(trifluoromethyl)phenyl]-3-nitrobenzamide | 1393911-15-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methyl-N-[4-methyl-3-(trifluoromethyl)phenyl]-3-nitrobenzamide
• CAS: 1393911-15-3
• 化学式: C₁₆H₁₃F₃N₂O₃
• 分子量: 338.286
• InChiKey: OZPMMAQTYJFJHU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-methyl-N-[4-methyl-3-(trifluoromethyl)phenyl]-3-nitrobenzamide 在 sodium cyanoborohydride 、 溶剂黄146 、 tin(ll) chloride 作用下， 以 甲醇 、 乙醇 、 乙酸乙酯 为溶剂， 反应 0.42h， 生成
  参考文献：
  名称：

  Discovery of VU6015929: A Selective Discoidin Domain Receptor 1/2 (DDR1/2) Inhibitor to Explore the Role of DDR1 in Antifibrotic Therapy

  摘要：

  Herein, we report the discovery of a potent and selective dual DDR1/2 inhibitor, 7e (VU6015929), displaying low cytotoxicity, good kinome selectivity, and possessing an acceptable in vitro DMPK profile with good rodent in vivo pharmacokinetics. VU6015929 potently blocks collagen-induced DDR1 activation and collagen-IV production, suggesting DDR1 inhibition as an exciting target for antifibrotic therapy.

  DOI：

  10.1021/acsmedchemlett.9b00382
• 作为产物：
  描述：

  4-甲基-3-硝基苯甲酸 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 4-methyl-N-[4-methyl-3-(trifluoromethyl)phenyl]-3-nitrobenzamide
  参考文献：
  名称：

  Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR–ABL kinase

  摘要：

  A series of acrylamide analogues were designed and synthesized from Imatinib and Nilotinib as novel BCR-ABL inhibitors by application of the principle of nonclassical electronic isostere. All new compounds were evaluated for their inhibitory effects on the activity of BCR-ABL kinase and the proliferation of K562 leukemia cancer cells in vitro. The acrylamide analogues in which the substituent in C ring was trifluoromethyl group were identified as highly potent BCR-ABL kinase inhibitors. Compound 13f exhibited an IC50 value as low as 20.6 nM in ABL kinase inhibition and an IC50 value of 32.3 nM for antiproliferative activity, about 10.5-fold and 12-fold lower than those of Imatinib respectively. These results suggest that compound 13f is a promising candidate as a novel BCR-ABL kinase inhibitor for further development. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.044